Corporate Profile
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells.
Latest Reports
Responsibility
Environmental, Social and Governance
At Geron, we strive to make a difference for patients with blood cancer so they can enjoy a better future, while endeavoring to make a broader positive impact. We do so through efforts related to our Environmental, Social and Governance (ESG) pillars: Healthier People, Human Capital, and Governance. We look forward to all that is ahead for Geron and the treatment of patients with blood cancer.
